Table A2.
n-3 treatment effect on one-year percentage change in FAs, oxylipins and small bioactive lipid features in VITAL200.
| Annotation or m/z RT | Assay | Median % Change | IQR |
|---|---|---|---|
| 528.2974 5.38 | LCMS | −29 | (−52–20) |
| 475.2657 4.13 | LCMS | −26 | (−47–18) |
| 474.2627 4.13 | LCMS | −26 | (−47–19) |
| RBC_DPAn6 | RBC | −25 | (−39−10) |
| RBC_Adrenic | RBC | −24 | (−32–7) |
| 502.2943 5.62 | LCMS | −24 | (−44–5) |
| 451.2623 4.42 | LCMS | −20 | (−47–6) |
| 450.2628 4.43 | LCMS | −20 | (−47–7) |
| 532.2654 4.43 | LCMS | −19 | (−46–9) |
| 604.3627 5.07 | LCMS | −17 | (−40–2) |
| 561.3002 5.73 | LCMS | −13 | (−32–5) |
| 502.2874 4.59 | LCMS | −12 | (−24–5) |
| 500.2787 4.62 | LCMS | −12 | (−25–5) |
| 600.2039 4.8 | LCMS | −11 | (−22–5) |
| 501.2818 4.61 | LCMS | −11 | (−25–4) |
| 503.2859 4.8 | LCMS | −10 | (−28–2) |
| 502.2846 4.8 | LCMS | −10 | (−26–0) |
| 500.2794 4.8 | LCMS | −10 | (−24–0) |
| 501.2821 4.8 | LCMS | −9 | (−23–1) |
| 441.2109 2.3 | LCMS | −9 | (−25–5) |
| RBC_AA | RBC | −8 | (−13−1) |
| 583.2847 4.8 | LCMS | −6 | (−16–0) |
| RBC_DGLA | RBC | −6 | (−11–2) |
| 582.2814 4.8 | LCMS | −5 | (−16–2) |
| RBC_DPAn3 | RBC | 17 | (5–34) |
| oxylipin1 | LCMS | 17 | (−3–59) |
| 527.286 4.69 | LCMS | 17 | (−3–53) |
| 326.2216 6.28 | LCMS | 20 | (−10–82) |
| 5-oxoETE | LCMS | 23 | (−11–66) |
| DHA | LCMS | 24 | (2–49) |
| 364.2088 6.45 | LCMS | 28 | (2–77) |
| 363.209 6.44 | LCMS | 30 | (1–78) |
| 17-HDoHE | LCMS | 30 | (−6–113) |
| 444.1595 2.2 | LCMS | 30 | (−8–85) |
| 365.2064 6.44 | LCMS | 33 | (−1–87) |
| RBC_DHA | RBC | 37 | (17–56) |
| 329.1724 4.91 | LCMS | 37 | (−6–96) |
| 325.218 6.28 | LCMS | 39 | (−5–99) |
| PL_DHA | PL | 40 | (14–63) |
| 12-HEPE | LCMS | 43 | (4–127) |
| oxylipin2 | LCMS | 45 | (−5–130) |
| 247.1704 5 | LCMS | 47 | (−2–139) |
| 5-HEPE | LCMS | 50 | (9–130) |
| 247.1705 4.91 | LCMS | 50 | (0–150) |
| RBC_O3i | RBC | 51 | (23–67) |
| PL_O3i | PL | 51 | (19–81) |
| EPA | LCMS | 61 | (24–131) |
| RBC_O3:6i | RBC | 63 | (27–92) |
| PL_O3:6i | PL | 64 | (16–111) |
| PL_EPA | PL | 83 | (25–220) |
| RBC_EPA | RBC | 112 | (45–238) |
| Palmitic Acid (Acetate Adduct) | LCMS | 200 | (23–456) |
Percentage change was calculated as . IQR—interquartile range. Assays: LCMS—high-throughput liquid chromatography–mass spectrometry of circulating free FAs, oxylipins and bioactive lipids from plasma; RBC—gas chromatography with flame ionization detection for red blood cells; PL—LCMS2 plasma phospholipids. Annotations for LCMS assay are putative. FAs, oxylipins and small bioactive lipid features with annotations and top 30 un-annotated ones (based on p-values) are shown.